Cargando…

Correlational Analysis of ALS Progression and Serum NfL Measured by Simoa Assay in Chinese Patients

Background: Neurofilament light chain (NFL) was believed to be a promising biomarker for the diagnosis of Amyotrophic lateral sclerosis (ALS) and disease burden evaluation. Objective: To determine the serum NFL level and its clinical relevance, including its association with disease severity [evalua...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sugimoto, Kazuo, Han, Yi, Song, Yuebo, Gao, Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7793911/ https://www.ncbi.nlm.nih.gov/pubmed/33424740 http://dx.doi.org/10.3389/fneur.2020.579094

Ejemplares similares

NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study: Serum NfL predicts relapse-free progression
por: Uphaus, Timo, et al.
Publicado: (2021)

A Score Based on NfL and Glial Markers May Differentiate Between Relapsing–Remitting and Progressive MS Course
por: Huss, André, et al.
Publicado: (2020)

SIMOA-based analysis of plasma NFL levels in MCI and AD patients: a systematic review and meta-analysis
por: Sahrai, Hadi, et al.
Publicado: (2023)

Neurofilament light (NfL) as biomarker in serum and CSF in status epilepticus
por: Margraf, Nils G., et al.
Publicado: (2023)

Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis
por: Barro, Christian, et al.
Publicado: (2022)

NfL and pNfH are increased in Friedreich’s ataxia
por: Hayer, Stefanie Nicole, et al.
Publicado: (2020)

Serum NfL in Alzheimer Dementia: Results of the Prospective Dementia Registry Austria
por: Kern, Daniela, et al.
Publicado: (2022)

Minocycline treatment in clinically isolated syndrome and serum NfL, GFAP, and metalloproteinase levels
por: Camara-Lemarroy, Carlos, et al.
Publicado: (2022)

Combined use of CSF NfL and CSF TDP‐43 improves diagnostic performance in ALS
por: Kasai, Takashi, et al.
Publicado: (2019)

NfL as a biomarker for neurodegeneration and survival in Parkinson disease
por: Bäckström, David, et al.
Publicado: (2020)

The Role of Serum Levels of Neurofilament Light (NfL) Chain as a Biomarker in Friedreich Ataxia
por: Frempong, Bernice, et al.
Publicado: (2021)

Cortical Thickness and Serum NfL Explain Cognitive Dysfunction in Newly Diagnosed Patients With Multiple Sclerosis
por: Cruz-Gomez, Álvaro J., et al.
Publicado: (2021)

Plasma NfL and GFAP as biomarkers of spinal cord degeneration in adrenoleukodystrophy
por: van Ballegoij, Wouter J. C., et al.
Publicado: (2020)

Comparison of Simoa(TM) and Ella(TM) to assess serum neurofilament‐light chain in multiple sclerosis
por: Gauthier, Audrey, et al.
Publicado: (2021)

Serum NfL levels in the first five years predict 10-year thalamic fraction in patients with MS
por: Lokhande, Hrishikesh, et al.
Publicado: (2022)

Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder
por: Hansson, Oskar, et al.
Publicado: (2017)

Amyotrophic lateral sclerosis: Correlations between fluid biomarkers of NfL, TDP-43, and tau, and clinical characteristics
por: Kojima, Yuta, et al.
Publicado: (2021)

Quantification and prospective evaluation of serum NfL and GFAP as blood-derived biomarkers of outcome in acute ischemic stroke patients
por: Ferrari, Federica, et al.
Publicado: (2023)

Ella versus Simoa Serum Neurofilament Assessment to Monitor Treatment Response in Highly Active Multiple Sclerosis Patients
por: Nötzel, Martin, et al.
Publicado: (2022)

Effect of Estimated Blood Volume and Body Mass Index on GFAP and NfL Levels in the Serum and CSF of Patients With Multiple Sclerosis
por: Yalachkov, Yavor, et al.
Publicado: (2022)

Emergence delirium and postoperative delirium associated with high plasma NfL and GFAP: an observational study
por: Liu, Xingyang, et al.
Publicado: (2023)

Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
por: Schindler, Patrick, et al.
Publicado: (2021)

An Update on Blood-Based Markers of Alzheimer’s Disease Using the SiMoA Platform
por: Li, Danni, et al.
Publicado: (2019)

Quantification of SNAP-25 with mass spectrometry and Simoa: a method comparison in Alzheimer’s disease
por: Nilsson, Johanna, et al.
Publicado: (2022)

Plasma Neurofilament Light (NfL) in Patients Affected by Niemann–Pick Type C Disease (NPCD)
por: Dardis, Andrea, et al.
Publicado: (2021)

Elevated serum Neurofilament Light chain (NfL) as a potential biomarker of neurological involvement in Myotonic Dystrophy type 1 (DM1)
por: Nicoletti, Tommaso F., et al.
Publicado: (2022)

The Use of Biologics in NFL Athletes: An Expert Consensus of NFL Team Physicians
por: Murray, Iain R., et al.
Publicado: (2023)

Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Aβ-PET and cognition
por: Rauchmann, Boris Stephan, et al.
Publicado: (2021)

Sex Differences in Behavioral Symptoms and the Levels of Circulating GFAP, Tau, and NfL in Patients With Traumatic Brain Injury
por: Sass, Dilorom, et al.
Publicado: (2021)

Characterizing plasma NfL in a community‐dwelling multi‐ethnic cohort: Results from the HABLE study
por: O'Bryant, Sid, et al.
Publicado: (2021)

Effect of Posterior Glenoid Labral Tears at the NFL Combine on Future NFL Performance
por: Murphy, Colin P., et al.
Publicado: (2018)

Epidemiology of Navicular Injury at the NFL Combine and Their Impact on an Athlete’s Prospective NFL Career
por: Vopat, Bryan, et al.
Publicado: (2017)

Can NFL Combine Results be Used to Estimate NFL Defensive Players Longevity?
por: Pollock, Jordan Riley, et al.
Publicado: (2021)

Cerebrospinal Fluid Neurofilament Light Chain (NfL) Predicts Disease Aggressiveness in Amyotrophic Lateral Sclerosis: An Application of the D50 Disease Progression Model
por: Dreger, Marie, et al.
Publicado: (2021)

Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231
por: Bayoumy, Sherif, et al.
Publicado: (2021)

Serum Sphingosine 1-Phosphate (S1P): A Novel Diagnostic Biomarker in Early Acute Ischemic Stroke
por: Liu, Jia, et al.
Publicado: (2020)

Neurochemical Monitoring of Traumatic Brain Injury by the Combined Analysis of Plasma Beta-Synuclein, NfL, and GFAP in Polytraumatized Patients
por: Halbgebauer, Rebecca, et al.
Publicado: (2022)

Truth, Justice, and the NFL Way: Review: League of Denial: The NFL, Concussions, and the Battle for Truth
por: Stieg, Philip E.
Publicado: (2014)

Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis
por: De Meyer, Steffi, et al.
Publicado: (2020)

Neurofilament-light chain quantification by Simoa and Ella in plasma from patients with dementia: a comparative study
por: Truffi, Marta, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6rriuo83lkab5s9r2pai40lri3